+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Bioengineered Protein Drugs Market by Drug Type, Disease, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011369
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Bioengineered Protein Drugs Market grew from USD 387.03 billion in 2023 to USD 415.13 billion in 2024. It is expected to continue growing at a CAGR of 7.76%, reaching USD 653.35 billion by 2030.

Bioengineered protein drugs, also known as biopharmaceuticals, are therapeutic products derived from living organisms using biotechnology. These include monoclonal antibodies, cytokines, and recombinant proteins that target specific biological pathways to treat various diseases, ranging from cancers and autoimmune disorders to infectious diseases. The increasing prevalence of chronic diseases, alongside advances in recombinant DNA technology, necessitates the burgeoning application of these drugs in precision medicine. End-use scope includes healthcare facilities, clinics, and research institutions, with an expanding reach into personalized treatment solutions. Market insights reveal that factors such as strategic collaborations, rising investments in research and development, and innovative drug delivery systems propel growth. Companies are capitalizing on biopharmaceutical pipelines, with geographic expansion into emerging markets further enhancing market potential. However, challenges such as regulatory complexities, high development costs, and stringent approval processes may hamper growth. Additionally, competition from biosimilars poses a significant threat. Despite these challenges, technological advancements in bioprocessing, automation, and digital health solutions present lucrative opportunities. Hybrid models integrating AI and machine learning in drug development promise accelerated innovation cycles and cost efficiencies. Technological collaborations and adaptive manufacturing frameworks can also propel market leadership. For businesses, fostering partnerships with academic and research institutions can enhance early-stage drug discovery and innovation. The bioengineered protein drugs market is dynamic, with growth heavily dependent on regulatory landscapes, ethical considerations, and technological advancements. Companies are encouraged to pursue a robust lifecycle management strategy, focusing on drug efficacy and safety. By navigating these factors effectively, businesses can capture emerging opportunities, making strategic investments in cutting-edge technologies and expanding involvement in collaborative research initiatives. Moreover, a strong emphasis on patient-centric approaches and real-world evidence integration will be pivotal in ensuring long-term market success and sustainability.

Understanding Market Dynamics in the Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing healthcare awareness and significant benefits of bioengineered protein drugs
    • Increase in healthcare spending across economies
  • Market Restraints
    • High costs associated with the bioengineered protein drugs
  • Market Opportunities
    • Growing research activities to develop and introduce novel bioengineered protein drugs
    • Emerging applications of nanotechnology in macromolecules delivery
  • Market Challenges
    • Stringent and time consuming approval processes

Exploring Porter’s Five Forces for the Bioengineered Protein Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Bioengineered Protein Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bioengineered Protein Drugs Market

External macro-environmental factors deeply influence the performance of the Bioengineered Protein Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioengineered Protein Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambrx, Inc., AMGEN INC., Aravive, Inc., Astrazeneca PLC, Baxter Healthcare, Bayer Pharmaceuticals, BRISTOL-MYERS SQUIBB, CSL LTD., F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, GRIFOLS S.A., Hoffman-la-Roche, MERCK & CO., INC., NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., Polaris Group, REGENERON PHARMACEUTICALS INC., SANOFI, and TAKEDA PHARMACEUTICAL CO., LTD..

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Monoclonal Antibodies
    • Therapeutic Proteins
    • Vaccines
  • Disease
    • Arthritis
    • Autoimmune Disorders
    • Blood Disorders
    • Cancer
    • Congenital Diseases
    • Heart Diseases
    • Infectious Diseases
    • Neurodegenerative Diseases
    • Respiratory Diseases
    • Skin Diseases
  • End-User
    • CROs
    • Pharmaceutical and Biotechnology Companies
    • Research institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of chronic diseases among population
5.1.1.2. Growing healthcare awareness and significant benefits of bioengineered protein drugs
5.1.1.3. Increase in healthcare spending across economies
5.1.2. Restraints
5.1.2.1. High costs associated with the bioengineered protein drugs
5.1.3. Opportunities
5.1.3.1. Growing research activities to develop and introduce novel bioengineered protein drugs
5.1.3.2. Emerging applications of nanotechnology in macromolecules delivery
5.1.4. Challenges
5.1.4.1. Stringent and time consuming approval processes
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bioengineered Protein Drugs Market, by Drug Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Therapeutic Proteins
6.4. Vaccines
7. Bioengineered Protein Drugs Market, by Disease
7.1. Introduction
7.2. Arthritis
7.3. Autoimmune Disorders
7.4. Blood Disorders
7.5. Cancer
7.6. Congenital Diseases
7.7. Heart Diseases
7.8. Infectious Diseases
7.9. Neurodegenerative Diseases
7.10. Respiratory Diseases
7.11. Skin Diseases
8. Bioengineered Protein Drugs Market, by End-User
8.1. Introduction
8.2. CROs
8.3. Pharmaceutical and Biotechnology Companies
8.4. Research institutes
9. Americas Bioengineered Protein Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bioengineered Protein Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bioengineered Protein Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOENGINEERED PROTEIN DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CONGENITAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 38. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 55. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 58. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 64. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 67. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 70. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 73. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 76. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 79. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 85. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 92. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 95. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 107. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 110. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 116. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 119. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 122. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 125. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 140. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 143. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 146. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 154. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Bioengineered Protein Drugs market, which are profiled in this report, include:
  • Abbott Laboratories
  • Ambrx, Inc.
  • AMGEN INC.
  • Aravive, Inc.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • BRISTOL-MYERS SQUIBB
  • CSL LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GRIFOLS S.A.
  • Hoffman-la-Roche
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.

Methodology

Loading
LOADING...

Table Information